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Identifying metabolic syndrome in a clinical cohort: Implications for prevention of
chronic disease
Abstract
In the clinical setting, calculating cardiovascular disease (CVD) risk is commonplace but the utility of the
harmonised equation for metabolic syndrome (MetS) (Alberti et al., 2009) is less well established. The
aims of this study were to apply this equation to an overweight clinical cohort to identify risk factors for
being metabolically unhealthy and explore associations with chronic disease. Baseline data were
analysed from a lifestyle intervention trial of Illawarra residents recruited in 2014/2015. Participants were
aged 25–54 years with a BMI 25–40 kg/m2. Data included MetS, CVD risk, insulin sensitivity, weight, body
fat, diet, peripheral artery disease (PAD), physical activity, socio-economic position and psychological
profile. Backward stepwise regression tested the association of covariates with MetS status and linear or
logistic regression tested associations between MetS and risk of CVD, coronary heart disease, PAD and
insulin resistance. 374 participants were included in the analysis with 127 (34.0%) categorised with MetS.
Covariates significantly and positively associated with MetS were higher BMI (odds 1.26, p < 0.01) and
older age (odds 1.08, p < 0.01). MetS participants (n = 351) had a 4.50% increase in CVD risk and were 8.1
and 12.7 times (respectively) more likely to be at risk of CHD and insulin resistance, compared to
participants without MetS. The utility of the harmonised equation in the clinical setting was confirmed in
this overweight clinical cohort. Those classified as having MetS were more likely to be older, overweight/
obese individuals and they had a substantially higher risk of developing CVD and insulin resistance than
those without MetS.
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Abstract
In the clinical setting, calculating cardiovascular disease (CVD) risk is commonplace but the utility of
the harmonised equation for metabolic syndrome (MetS) [1] is less well established. The aims of this
study were to apply this equation to an overweight clinical cohort to identify risk factors for being
metabolically unhealthy and explore associations with chronic disease.
Baseline data were analysed from a lifestyle intervention trial of Illawarra residents recruited in
2014/2015. Participants were aged 25-54 years with a BMI 25-40kg/m2. Data included MetS, CVD
risk, insulin sensitivity, weight, body fat, diet, peripheral artery disease (PAD), physical activity, socioeconomic position and psychological profile. Backward stepwise regression tested the association of
covariates with MetS status and linear or logistic regression tested associations between MetS and
risk of CVD, coronary heart disease, PAD and insulin resistance. 374 participants were included in the
analysis with 127 (34.0%) categorised with MetS. Covariates significantly and positively associated
with MetS were higher BMI (odds 1.26, p<0.01) and older age (odds 1.08, p<0.01). MetS participants
(n=351) had a 4.50% increase in CVD risk and were 8.1 and 12.7 times (respectively) more likely to
be at risk of CHD and insulin resistance, compared to participants without MetS.
The utility of the harmonised equation in the clinical setting was confirmed in this overweight clinical
cohort. Those classified as having MetS were more likely to be older, overweight/obese individuals
and they had a substantially higher risk of developing CVD and insulin resistance than those without
MetS.

Key Words: metabolically unhealthy; metabolic syndrome; cardiovascular disease risk; insulin
resistance; lifestyle factors; obesity

The study is registered with the ANZ Clinical Trial Registry (ANZCTRN12614000581662).
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Introduction
A decline in metabolic health often precedes cardiovascular disease (CVD) and diabetes mellitus, so
there are benefits in early identification and intervention. Definitions of “metabolically unhealthy”
vary. Investigators have frequently used either the absence of metabolic syndrome (MetS), high
insulin sensitivity, or a combination of both to define metabolic health in overweight or obese
individuals [2, 3]. A global definition of MetS now exists [1] that unifies previously published
equations with an agreement that central obesity is not an obligatory component. The harmonised
definition of MetS is defined as having three of the following: elevated waist circumference (country
specific guidelines), triglycerides ≥ 1.7mmol/L*, systolic blood pressure ≥130 or diastolic ≥85mmHg*,
glucose ≥ 100mg/dL and reduced HDL cholesterol <1.0 mmol/L (males) or <1.3mmol/L (females) (or
drug treatment as indicated*) [1]. Recently published studies have also been found to use previous
MetS equations [2, 4, 5]. While risk calculations of CVD are readily available [6, 7], the identification
of MetS is not commonly used in practise and could help initiate early intervention for disease
prevention.
MetS often occurs in the presence of obesity which is known to cause a decline in life expectancy
due to its associated metabolic and cardiovascular comorbid disorders. Clinical practice guidelines
for obesity defer to treatment with diet, physical1 activity and behavioural support [8]. However,
recent research suggests that not all obese individuals have the same metabolic risk profile [9] and
this has implications for personalising treatment. In the first instance it may be relevant to
distinguish individuals at high risk for obesity-related metabolic diseases by identifying the presence
of MetS.
In addition to traditional risk factors such as obesity, many other factors have been suggested as
being associated with MetS, such as chronic stress [10]; socioeconomic position [11];
cardiorespiratory fitness [12], peripheral artery disease (PAD) [13], and dietary saturated fatty acids
[4]. These all have implications for the mode of treatment, particularly in relation to the nature of
diet, exercise and psychological support.

1.

List of abbreviations

Metabolic Syndrome (MetS), body mass index (BMI), ankle brachial index (ABI), systolic blood pressure (SBP),
diastolic blood pressure (DBP), international physical activity questionnaire (IPAQ), depression anxiety stress
scale (DASS-21), cardiovascular disease (CVD), coronary heart disease (CHD).
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The aims of this study were to apply the harmonised equation for calculation of MetS to a clinical
cohort and to identify risk factors for being metabolically unhealthy, as well as assess presence of
MetS and risk of chronic disease.
Methods
Study Design and Setting
This paper reports on a secondary analysis of data from the HealthTrack study, a 12 month healthy
lifestyle randomised clinical trial. Participants were randomised to receiving either usual care
(general advice), or individualised dietary advice with exercise prescription and health coaching, with
or without a healthy food supplement (walnuts). Participants were recruited from the Illawarra
region of NSW between May 2014 and April 2015. Inclusion criteria for the study were: permanent
residents of the Illawarra region (NSW, Australia), adults aged 25-54 years, and with a body mass
index (BMI) in the range 25-40kg/m2. Exclusion criteria were: unable to communicate in English;
severe medical conditions, impaired ability to participate; suffering from immunodeficiency;
reported illegal drug use or regular alcohol intake (>50g/day). Ethical approval was granted by the
University of Wollongong/Illawarra Shoalhaven Local Health District Human Research Ethics
Committee (Health and Medical) (HE 13/189). Full written consent was obtained prior to study
commencement. The study is registered with the ANZ Clinical Trial Registry
(ANZCTRN12614000581662).
Full details of the protocol and methodology have previously been described [14]. In summary, at
baseline 377 participants had body weight (kg) and %body fat measured using scales with a bioelectrical impedance component. Fasting blood lipids (total cholesterol, LDL, HDL, triglycerides) and
blood glucose were collected and tested through a registered pathology service (Southern IML
Pathology). Systolic (SBP) and diastolic blood pressure (DBP) was measured using the Omron BP203RPEIII VP-1000 device (Omron Health Care, Kyoto, Japan). Arterial stiffness (baPWV) and arterial
occlusion (ankle brachial index - ABI) data were also collected from this device, giving a direct
measure of peripheral artery disease. An ABI of <0.90 or >1.40 was classified as indicative of
peripheral artery disease, ABI between 0.90 and 1.00 was classified as at risk of peripheral artery
disease, and ABI between 1.01 and 1.39 was classified as healthy. Dietary intake was assessed using
4 day food records completed by participants, which included one weekend day. Dietary data was
analysed using FoodWorks software (Version 7, 2012, Xyris Software, Spring Hill, QLD, Australia).
Food intake data was converted to energy and macronutrient intake using the AUSNUT2007 food
composition database [15]. Physical activity was assessed using the International Physical Activity
Questionnaire (IPAQ) short form survey questions [16] and by a scientific grade pedometer (Yamax
4

Digiwalker SW200, Pedometers Australia) worn for 4 consecutive days to confirm an average
number of steps per day. Psychological profile was assessed using the Physical and Mental Quality
of Life Assessment (SF-12)[17] and the Depression Anxiety Stress Scale (DASS – 21)[18]. Socio
economic position was approximated by the use of level of education attained and the average
household income, which were both self-reported in an on-line population survey completed during
screening for the randomised controlled trial. These covariates were included in the analysis as they
are related to the three components of the lifestyle intervention which were implemented in the
HealthTrack study after the baseline assessment, those being: dietary counselling, exercise advice
and psychological coaching.
MetS was calculated using the harmonized definition [1], with waist circumference thresholds set at
the AHA/NHLBI (ATP III) levels of > 102 cm for males and >88cm for females. Participants were
categorised as MUO if MetS was present or MHO if no MetS was present. Framingham CVD and
coronary heart disease (CHD) risk were calculated based on the published CVD equations [6] and
CHD score sheets [7]. A risk percentage of less than 10% was categorised as ‘low risk’, and 10% or
more were categorised as ‘moderate to high risk’ (< 1% had a high risk of CVD and CHD, therefore
moderate and high risk categories were combined). Similarly, for ABI the peripheral artery disease
category (<0.90) was combined with the at risk category (0.91 – 1.00) for analysis. Insulin resistance
was defined as participants prescribed hypoglycaemic agents or a glycated haemoglobin (HbA1c)
level > 6%.
Statistical Analysis
The statistical package used for analysis was IBM SPSS Statistics (version 21.0, IBM Corp, Chicago IL,
2012). Analyses included baseline data from all participants recruited into the HealthTrack study.
The cross-sectional associations between physiological and lifestyle covariates and those classified as
having MetS were analysed using backward stepwise logistic regression. Covariates included
demographic (age, BMI, gender, % body fat); psychological (DASS-21, SF12 mental scale); physical
activity (IPAQ, steps/day); dietary (total kilojoules, total fat, monounsaturated fatty acid (MUFA),
polyunsaturated fatty acid (PUFA) and saturated fat); and social (education level, household
income). Predictors which achieved a p value <0.2 in univariate analysis were assessed for inclusion
in the multivariate model. The final model was checked using forward elimination (data not shown).
Linear regression was used to examine associations between incidence of MetS and CVD risk, whilst
logistic regression was used to test associations between MetS and CHD risk, peripheral artery
disease and insulin resistance.

5

Results
Of the 377 participants randomised, data required for calculation of MetS was available for 374, and
127 participants (34.0%) were classified with MetS (Table1). Multivariate analysis demonstrated that
having a higher BMI (odds 1.26, p<0.01) and older age (odds 1.08, p<0.01) were significantly and
positively associated with having MetS (Table 2). None of the other psychological, physical, dietary
or social factors had a significant association with MetS classification.
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Table 1: Baseline characteristics of Illawarra (NSW, Australia) participants
Baseline characteristic
DEMOGRAPHIC
Males/females (%)
Age (years)
Body mass index (kg/m2)
Body Fat (%) (n=371)
METABOLIC
Systolic blood pressure (mmHg)
HDL (mmol/L)
Total cholesterol (mmol/L)
Triglycerides (mmol/L)
Glucose (mmol/L)
Smoker/non-smoker (%) (n=373)
Waist circumference (cm)
PSYCHOLOGICAL
DASS depression (%high*)
DASS anxiety (%high*)
DASS stress (%high*)
DASS total
SF 12 mental (n=370)
PHYSICAL ACTIVITY
IPAQ (METS) (n=368)
Steps/day (n=294)
DIETARY
Total energy (kJ) (n=336)
Energy from fat (%)(n=336)
MUFA (% of fat) (n=336)
PUFA (% of fat) (n=336)
Saturated fat (% of fat) (n=336)
SOCIAL
University/post grad degree (%)
Household income < $80,000 (%)
Household income $80-159,999 (%)
Household income > $160,000 (%)
Income not recorded (%)
PHARMACOLOGICAL
Antihypertensive (%)
Hypolipidaemic (%)
Antidepressant/Antianxiety (%)
Data are expressed as mean + standard
moderate, severe and extremely severe)

MetS (n=127)

No Mets (n=247)

33/67
45.8 ± 6.6
35.1 ± 3.9
42.4 ± 6.6

23/77
42.0 ± 8.5
31.3 ± 3.8
39.4 ± 7.2

135.0 ± 14.9
1.2 ± 0.3
5.4 ± 1.1
1.8 ± 0.9
6.0 ± 1.7
5/95
110.6 ± 10.3

119.9 ± 12.7
1.5 ± 0.4
5.1 ± 0.9
1.2 ± 1.3
5.1 ± 0.6
4/96
99.9 ± 10.8

4.8 ± 4.3 (43.3)
3.1 ±3.2 (32.3)
6.8 ± 3.9 (38.6)
14.6 ±10.0
46.3 ±10.7

4.0 ± 4.0 (34.8)
2.6 ± 2.8 (25.9)
6.5 ± 4.2 (37.2)
13.1 ± 9.2
46.4 ± 9.6

1396.7 ± 1514.3
7012.1 ± 3030.2

1391.7± 1414.6
7931.5 ± 3042.2

9314.9 ± 2667.5
34.7 ± 5.7
40.2 ± 4.8
16.4 ± 4.3
43.4 ± 6.7

8861.6 ± 2343.9
34.6 ±5.0
40.6 ± 4.8
16.8 ± 4.6
42.6 ± 7.4

42
27
45
15
13

55
24
43
20
14

32.3
3.6
15.0
5.3
22.0
14.2
deviation or %, *proportion of high (including mild,
scores of depression ≥5, anxiety ≥4, and stress ≥8
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Table 2: Baseline demographic and lifestyle covariates assessed in the multivariate logistic regression model of presence of Mets of Illawarra (NSW,
Australia) participants
Category
Baseline variable
Univariate analysis
Multivariate analysis
Coefficient
Lower 95% CI Upper 95% CI
P
Odds
Lower 95% CI
Upper 95% CI
Demographic Age
0.14
0.01
0.02
<0.01
1.08
1.04
1.12
BMI
0.05
0.04
0.06
<0.01
1.26
1.18
1.36
Gender
-0.12
-0.23
-0.01
0.03
0.55
0.30
1.02
% Body Fat
0.01
0.01
0.02
<0.01
1.04
0.95
1.13
Psychological DASS Depression
0.01
-<0.01
0.02
0.19
1.03
0.96
1.10
DASS Anxiety
0.01
-0.01
0.03
0.21
DASS Stress
<0.01
-0.01
0.02
0.57
DASS Total
<0.01
-<0.01
0.01
0.23
SF-12 Mental
<0.01
-<0.01
0.01
0.82
Physical
activity
IPAQ
<0.01
<0.01
<0.01
0.64
#
Steps/day S1
-0.26
-0.48
-0.03
0.02
0.62
0.19
2.01
Steps/day S2#
-0.27
-0.46
-0.07
0.01
0.61
0.22
1.66
#
Steps/day S3
-0.20
-0.37
-0.04
0.02
0.65
0.28
1.49
#
Steps/day S4
-0.25
-0.41
-0.10
<0.01
0.55
0.25
1.18
Dietary
Total Kilojoules
<0.01
<0.01
<0.01
0.12
1.00
1.00
1.00
MUFA
-<0.01
-0.01
0.01
0.56
PUFA
-<0.01
-0.02
0.01
0.46
Sat Fat
<0.01
-<0.01
0.01
0.39
@
Social
Household Income C1
-0.09
-0.24
0.06
0.24
@
Household Income C2
-0.02
-0.14
0.10
0.75
Education L1*
-0.25
-0.91
0.42
0.47
Education L2*
-0.20
-0.86
0.46
0.56
Education L3*
-0.10
-0.77
0.56
0.76
Education L4*
-0.05
-0.74
0.64
0.89
Education L5*
-0.22
-0.90
0.46
0.53
8

P
<0.01
<0.01
0.06
0.46
0.43

0.43
0.33
0.31
0.12
0.23

Education L6*

-0.05

-0.73

0.63

0.89

l#

Gender uses male as the referent category. Steps/day S1 highly active, S2 active, S3 somewhat active, S4 low active. Steps per day are compared with sedentary as the
referent category. @Household income category C1 >$160,000, C2 $80 - $159,999. Household income compared with <$80,000 as the referent category. *Education L1
postgraduate degree, L2 university degree, L3 certificate/diploma, L4 trade/apprenticeship, L5 high school or leaving certificate, L6 school or intermediate certificate.
Education levels are compared with no school certificate or other qualification as the referent category

9

To examine CVD and CHD estimated risk, data were available for n=351 participants (Table 3). The
median risk of experiencing cardiovascular disease within the next 10 years for all participants
(interquartile range) was 3.89% (1.83 – 7.00). Most participants (88-92%) were in the low risk (<10%)
category. Using linear regression, participants classified with MetS had a 4.50% increase in CVD risk
compared to no-MetS participants (odds 4.50 (95% CI: 3.72, 5.28), p<0.01). Using logistic regression,
it was identified that MetS participants were 8.1 times more likely to be at risk of CHD than others
(odds 8.07 (95% CI: 3.16, 20.62), p<0.01).
Table 3: Estimated 10 Year Cardiovascular Disease (CVD) Risk and Coronary Heart Disease (CHD)
Risk (n=351) of Illawarra (NSW, Australia) participants
Risk category
Low (<10%)
Moderate (10 – 20%)
High (>20%)
1Based
2Based

CVD1
310 (88.3%)
39 (11.1%)
2 (0.6%)

CHD2
324 (92.3%)
26 (7.4%)
1 (0.3%)

on published equation [6]
on published score sheets [7]

A total of n=26 (6.9%) of participants were categorised as being insulin resistant (15 on prescribed
hypoglycaemic medication, 11 with HbA1c>6%). Using logistic regression, MetS participants were
found to be 12.7 times more likely to be insulin resistant (odds 12.73 (95% CI: 4.28, 37.85), p<0.01).
In contrast, analysis of available data for MetS and ABI (n=372) found that MetS did not significantly
predict peripheral artery disease (odds 0.91 (95% CI: 0.55, 1.51), p=0.72).
Discussion
Obesity is a public health problem that contributes significantly to the increasing prevalence of
chronic diseases such as diabetes mellitus and CVD. However, given that metabolic risk may differ
between obese individuals, the identification of those with MetS and the factors associated with this
risk may assist in developing approaches to preventive services, especially since metabolic
disturbances occur prior to the onset of chronic disease. These analyses provided some insights into
who is at risk of having MetS and to what degree individuals with MetS increase their risk of
developing chronic disease. The application of the harmonised equation proved useful in making this
identification in an overweight clinical cohort that interestingly identified increased risk in
developing CVD, CHD and insulin resistance but not PAD (as assessed using ABI). The latter may be
due to the specificity of the measurement, and it was noted that most of the participants were at
low risk of CVD. These results highlight the gaps between assessment of risk and the onset of
disease, and this has implications for assessing outcomes for lifestyle intervention. While it is
appropriate to identify at risk individuals and encourage lifestyle modification, a focus on behaviour
changes and indications of reduced risk may be more appropriate than reduced disease incidence.
10

The importance of measuring MetS in individuals has not been confirmed, however as prevention
programs aim to address individuals health issues before they develop into chronic disease, it may
become a vital assessment tool. Interest in the metabolic syndrome was high between 1997 and
2005, however since the most recent definition was published in 2009 [1], there appears to be a
paucity of data utilising the harmonised definition. Our study included healthy participants aged
between 25-54 years with a BMI in the range 24-40kg/m2. It is well documented that
overweight/obesity is the most important precursor for development of MetS [19], so our
participants represented those at greatest risk of MetS and at a point of greatest benefit from
lifestyle change, the primary treatment option. This sub-analysis of the HealthTrack clinical trial at
baseline demonstrated that amongst the many factors included in the analysis, only older age and
higher BMI predicted the presence of MetS, as classified by the harmonised equation. As the
development of MetS begins with excess central adiposity, the findings were not surprising, due to
the prevalence of abdominal obesity in older overweight individuals [20]. Still, our analysis confirms
the results of previous studies that have reported BMI and age to be associated with MetS [21] in
large national surveys using the ATPIII criteria.
Those classified as MetS in this cohort were associated with a higher percentage risk of developing
CHD or CVD within the next ten years and of developing diabetes mellitus; however we were not
able to predict peripheral artery disease, as indicated by ABI. The diagnosis of MetS is reported to
increase the risk of CVD by 30-400%, with the variation likely due to differing definitions, populations
studied, and length of follow-up [22-24]. In our cohort characterised by a low prevalence of
moderate-high CVD risk (7-11%), those diagnosed with MetS had a 4.50% increase in CVD risk and
were eight times more likely to develop CHD within the next 10 years compared to participants
without MetS. A low ABI has previously been reported in participants with MetS [13]. We did not
find an association between participants with MetS and low ABI, but our study only contained a
small proportion of participants diagnosed with peripheral artery disease.
Insulin resistance was strongly associated with MetS in our analyses, with a 12.7 times greater risk
compared to individuals without MetS. This finding is similar to another study examining obese
subjects with MetS that reported an adjusted relative risk of 10.3 for diabetes [25]. These findings
are expected as insulin resistance is strongly and positively associated with BMI, most likely due to
increased liver and visceral fat content and the associated inflammatory signalling [26].
We also examined other lifestyle factors. The effect of psychosocial stress on MetS appears to be
reciprocal in that chronic stress induces MetS as well as the associated hormonal dysfunctions of
MetS augment cortisol-induced stress [27]. More recently however, the GEA study indicated that
11

self-reported chronic stress did not predict MetS [28]. Our current analyses did not show any
significant association between stress, anxiety, depression or quality of life and MetS. This may be
due to the indirect methods used to assess mental health, which were similar to that used in the
GEA study. In addition, Brunner et al [27] only demonstrated an association in male participants,
whereas our study sample was predominantly female.
From a broader social perspective, lower social position has been suggested as increasing the
probability of MetS [11], as well as a low education level [29]. In contrast, our analyses found neither
education level nor household income were significantly associated with MetS. The difference could
be explained in terms of larger sample sizes (n= 8104 and 4341 respectively vs n=377), and different
equations, but they also point to important differences in context. In the clinical decision making,
education level and income may not be as relevant as they are for population health strategies.
Physical activity is another important consideration. Low cardiorespiratory fitness has been
suggested as a predictor of MetS in a large cohort with BMI 22-25 kg/m2 [12]. Our data did not
confirm this finding which may be due to the greater BMI of our clinical cohort. From a dietary
perspective, dietary fatty acids of vegetable origin may have a beneficial effect on the incidence of
MetS [4]. In our analyses no significant association was found between dietary fatty acids and MetS,
however the sample size was possibly too small to detect these associations given variations in food
choices.
The main limitation of our sub-study is that MetS and lifestyle factors were secondary outcome
measurements and the sample size was not specifically powered for addressing the relationships
considered here. Likewise, the HealthTrack population was generally healthy and middle-aged albeit
overweight, and this differed to other studies investigating younger or older populations. However
from a public health and primary healthcare perspective it is most important to identify MetS in its
earlier stages, that is, when people are healthy and before they develop CVD or insulin resistance.
One other limitation was the use of medication, other than those included in the calculation of
MetS, CVD, CHD and insulin resistance; they were not adjusted for in the multivariate analysis.
Conclusions
This study examined the utility of the harmonised equation for assessment of MetS in a clinical
cohort of healthy overweight/obese volunteers and confirmed that those at greatest risk are older,
overweight individuals. Once MetS is identified it is important to implement multi-disciplinary
lifestyle changes due to the strong correlation with cardiovascular disease and insulin resistance. The
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classification of MetS will also be useful in determining the relative effects of lifestyle intervention
over time.
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